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Abstract 
BACKGROUND: Hydroxyurea (HU) is an antimetabolite agent that interferes with the S-phase of cellular 
replication and inhibits DNA synthesis, with little or no effect on RNA or protein synthesis. It is used in the 
treatment of many myeloproliferative disorders (MD) and is particularly a first line treatment drug for intermediate 
to high-risk essential thrombocythemia. Although safe and very well tolerated by the patients suffering from MD, 
there have been numerous reports of a broad palette of cutaneous side effects associated with prolonged intake 
of the medication. These may include classical symptoms such as xerosis, diffuse hyperpigmentation, brown-nail 
discolouration, stomatitis and scaling of the face, hands, and feet or more serious side effects such as actinic 
keratosis lesions, leg ulcers and multiple skin carcinomas.  
CASE REPORT: We report a case of a 52-year-old man, on long-term therapy with HU for essential 
thrombocytosis, with several concurrent skin lesions. Despite the perennial use of HU, the cutaneous changes 
were neglected. The local dermatological examination revealed oval perimalleolar ulcer on the right leg, with 
dimensions 6 x 4 cm, clearly demarcated from the surroundings with regular margins, periulcerous erythema, with 
very deep and highly fibrinous bed of the ulcer, positive for bacterial infection. The ulcer was treated with topical 
wound therapy with alginate and parenteral antibiotics. The extended dermatological screening also showed two 
nummular lesions in the right brachial region, presenting as erythematous papules with sharp margins from the 
surrounding skin, gritty desquamation and dotted hyperpigmentations inside the lesion. Further dermoscopy and 
biopsy investigations confirmed a diagnosis of basal cell carcinoma. Nasal actinic keratosis was also noted. The 
patient was advised for discontinuing or substituting the HU therapy.  
CONCLUSION: We present this case to draw attention to the various cutaneous side effects that occur with 
perennial HU use and suggest an obligatory reference to a dermatological consult. 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
Hydroxyurea (HU), a hydroxylated molecule 
of urea, is an antimetabolite drug that interferes with 
the synthesis of DNA, with little or no effect on RNA or 
protein synthesis [1][2]. It is used in the treatment of 
many myeloproliferative disorders (MD) such as 
chronic myeloid leukaemia, polycythemia vera or 
management of other diseases like sickle cell 
anaemia or thalassemia [3]. It is particularly a drug of 
choice as a first-line treatment for intermediate to 
high-risk essential thrombocythemia [4]. Although safe 
and very well tolerated by the patients suffering from 
MD with primary thrombocytosis [5], there have been 
numerous reports of cutaneous side-effects 
associated with prolonged intake of the medication [6]. 
These include major skin changes as actinic keratosis 
lesions, leg ulcers and multiple skin carcinomas, [6][7] 
with leg ulcers affecting as many as 9% of HU-treated 
patients [8]. 
The objective of our report is to raise 
awareness of the possible cutaneous lesions induced 
by long-term use of hydroxyurea. 
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Case report 
 
A 52 years old Caucasian male patient, 
affected by essential thrombocytosis on perennial 
therapy of more than 10 years with hydroxyurea, 
presented to the Department of Dermatology with 
painful leg ulceration.  
The patient has experienced two myocardial 
infarctions in the past (2001/2013) which was both 
treated with angioplasty through stent placement. He 
also had an episode of bleeding gastric erosion. 
Moreover, the patient suffers from hypertension. The 
chronic therapy that the patient receives is as follows: 
Furosemide, Carvedilol, Acetylsalicylic acid and 
Lisinopril. After being diagnosed with essential 
thrombocytosis, the patient is on a perennial therapy 
with hydroxyurea (1.5 g/day). 
Eight months before the examination, the 
patient reports an oval skin defect in the perimalleolar 
region of the right leg, which he does not associate 
with a mechanical injury. He was never referred to a 
regular check-up. Owing to the neglected nature of 
the problem, the lesion progressed with ulceration and 
became very painful. The patient treated the lesion 
himself, with dough, sugar and alcohol-
unsuccessfully, after which he presented himself to 
the Department of Dermatology. The local 
dermatological examination revealed oval 
perimalleolar ulcer on the right leg, with dimensions 6 
x 4 cm, clearly demarcated from the surroundings with 
regular margins and definite limits, periulcerous 
erythema and hyperalgesia over the lesion, all the 
way down to the foot. The bed of the ulcer appeared 
very deep, involving cutaneous and subcutaneous 
tissues, highly fibrinous and showed signs of bacterial 
infection. The microbiological smear was performed 
and came back positive with a Staphylococcus 
aureus, Streptococcus  haemolyticus and 
Enterococcus contamination. The patient was treated 
with parenteral antibiotics by antibiogram 
(Clindamycin), as well as topical wound therapy with 
alginate. Doppler sonography and 
photoplethysmography were also commenced, by 
which vascular etiology of the ulcer was excluded. A 
consultation with a hematologist was advised right 
away for discontinuing or substituting the HU therapy. 
A consultation with a hematologist was advised right 
away for discontinuing HU therapy and substituting it 
with recommended second-line therapy with 
pegylated IFN-α. Treatment with barotherapy was 
introduced and shaving and meshed graft 
transplantation planned after cleaning the bed ulcer. 
The patient was then examined for other 
cutaneous side effects. The dermatological screening 
revealed two nummular lesions in the right brachial 
region, presenting as erythematous papules with 
sharp margins from the surrounding skin, gritty 
desquamation and dotted hyperpigmentations inside 
the lesions.  
 
Figure 1: a), b) Oval perimalleolar ulcer on the right leg, with 
dimensions 6 x 4 cm, clearly demarcated from the surroundings 
with regular margins and definite limits, periulcerous erythema. The 
bed of the ulcer appears very deep and highly fibrinous. The a and 
b figures are respectively time framed to cover 5 months, from initial 
examination (Fig. 1a) to last control (Fig. 1b). We see no significant 
change in the course of treatment 
 
When asked, the patient reported that he 
detected them several years ago and recorded 
discreet bleeding with mechanical trauma and crust 
formation over time, but the changes were also 
neglected, and he did not report them to a doctor 
before. A dermoscopy was initiated, which supported 
the initial suspicion of a cancer lesion. 
 
Figure 2: a), b) and c) Two nummular lesions (Fig. 2 b upper lesion, 
Fig. 2 c lower lesion) in the right brachial region, presenting as 
erythematous papules with sharp margins from the surrounding 
skin, gritty desquamation and dotted hyperpigmentations inside the 
lesion  
 
Per protocol, biopsy followed, and the 
histopathological findings sustained basal cell 
carcinoma (BCC). The patient was advised for 
surgical treatment of the lesions. 
 
Figure 3: a), b) (upper lesion), c), d) (lower lesion) Dermoscopic 
findings of cancer like lesions: shiny white to red areas, short fine 
telangiectasias, leaf-like areas and small surface erosions 
1a 
1b 
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Furthermore, an actinic keratosis lesion in the 
nasal region was to be noted, which was 
dermoscopically verified. The treatment of choice was 
cryotherapy, with a successful outcome.  
 
Figure 4: Nasal actinic keratosis lesion 
 
 
 
Discussion 
 
Essential thrombocythemia is a 
myeloproliferative disorder, characterised by stem 
cell-derived clonal myeloproliferative. The therapeutic 
approach is directly influenced by the risk grade of the 
disease, which is determined by the extensity of 
thrombocytosis, history and advanced age [3]. Thus, 
our patient is classified as an intermediate to high-risk 
thrombocytosis. 
As presented by Tefferi et al., (2018) the 
current treatment algorithm for intermediate and high-
risk ET is hydroxyurea as a first line drug of choice 
and a low dose of Aspirin [4], guidelines, which were 
correspondingly followed for the disorder 
management in our case.  
HU is an antimetabolite agent, which acts 
upon the S-phase of cellular replication and inhibits 
DNA synthesis by barring the ribonucleotide 
reductase but does not affect RNA synthesis [1] [2]. 
As expected by an antineoplastic medication, Guillot 
et al., (2004) illustrate a broad palette of skin-related 
side effects associated with the long-term utilisation of 
the drug [7]. These may include classical symptoms 
such as xerosis, diffuse hyperpigmentation, brown-nail 
discoloration, stomatitis, erythema, and scaling of the 
face, hands, and feet, but three cutaneous lesions, in 
particular, are more specific to this drug: leg ulcers, 
actinic keratosis and increased frequency of skin 
carcinomas [2] [7] [9]. As in numerous other cases, 
our patient underwent cutaneous changes which are 
believed to be closely related to the long-term use of 
1.5 g daily dose of HU. Most strikingly observant is the 
leg ulcer.  
Stahl and Silber (1985) were the first one to 
report an HU-induced leg ulcer in 1985 [10]. 
Quattrone et al., (2013) appraised a pathophysiologic 
theory of three pathogenic factors in the formation of 
HU-induced skin ulcers- minor external traumas, 
direct HU toxicity on basal cells and hypoxia due to 
HU-induced macrocytosis [9]. Multiple publications 
show similarities to our case regarding the proposed 
aetiology of the leg ulcer. Consistently, dosage and 
duration of HU administration, as well as the location 
of the ulcer and the progression of the lesion: long-
term use of HU (> 5 years), (1 or 1.5 mg per day), 
very painful perimalleolar ulcers, with no prior trauma 
[5] [11] [12] [13] [14]. Notwithstanding the standard 
wound therapy, treatment of choice in HU-induced leg 
ulcers is discontinuation of the drug or substitution 
therapy [8]. In contrast, there were few cases, where 
only standard debridement therapy, without 
discontinuation of HU, was enough to achieve 
successful partial or complete remission of the ulcers 
[6] [11] [13]. Correspondingly to some publications [6] 
[13] [14], our case showed refraction to standard 
conservative therapy. Hence a consultation with a 
haematologist for discontinuation and substituting it 
with recommended second-line therapy with 
pegylated IFN-α was commenced [4]. 
We also report of two carcinoma-like lesions, 
which were thoroughly examined according to 
protocol. As the physical examination and 
dermoscopy gave ambiguous findings, a biopsy was 
indicated. The result was a histopathological image of 
BCC. The significance of reporting these lesions is by 
other publications of similar lesions, with similar 
dermatological status, but histopathologically proven 
SCC [6]. Consequently, we advise an in-depth 
examination of all cancer-like lesions, due to the 
broad spectrum of different possible pathohistological 
findings.  
The actinic keratosis lesion is reported within 
this paper, not only in association with HU [6] but 
because of its pre-malignant nature and high rate of 
malignisation, so a detailed follow-up is always 
advised.  
In conclusion, our case study highlights the 
importance of understanding the cutaneous side 
effects of long-term HU use. Haematologists and 
patients should be drawn to attention to cutaneous 
lesions induced by prolonged HU intake. If there are 
skin changes already present, substitute therapy 
should always be advised if possible. Dermatological 
consult ought to be mandatory for all patients on 
perennial HU use.  
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